Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children

No abstract is available for this paper.

• Publication year

  2017

• Venue

  The Pediatric Infectious Disease Journal

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/INF.0000000000001687PMID 28719501PMCID PMC5744601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose rifampicin, moxifl oxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

  2019cited by this paper
• High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

  2017cited by this paper
• Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.

  2016cited by this paper
• Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial

  2016cited by this paper
• Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines

  2016cited by this paper
• Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests

  2016cited by this paper
• Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection

  2016cited by this paper
• Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients.

  2015cited by this paper
• Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

  2015cited by this paper
• The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

  2015cited by this paper
• Antituberculosis drugs in children

  2015cited by this paper
• Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.

  2014cited by this paper
• Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update

  2014cited by this paper
• Pharmacokinetics of First-Line Antituberculosis Drugs in HIV-Infected Children with Tuberculosis Treated with Intermittent Regimens in India

  2014cited by this paper
• Contradictory Results with High-Dosage Rifamycin in Mice and Humans

  2013cited by this paper
• Requirements for the clinical evaluation of new anti-tuberculosis agents in children.

  2013cited by this paper
• Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to Treatment Response in Indonesian Pulmonary Tuberculosis Patients

  2013cited by this paper
• Therapeutic Drug Monitoring in the Treatment of Tuberculosis

  2012cited by this paper
• Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.

  2012cited by this paper
• The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children.

  2011cited by this paper
• COORDINATE DESCENT ALGORITHMS FOR NONCONVEX PENALIZED REGRESSION, WITH APPLICATIONS TO BIOLOGICAL FEATURE SELECTION.

  2011cited by this paper
• Pharmacokinetics of Isoniazid, Rifampin, and Pyrazinamide in Children Younger than Two Years of Age with Tuberculosis: Evidence for Implementation of Revised World Health Organization Recommendations

  2011cited by this paper
• Nearly unbiased variable selection under minimax concave penalty

  2010cited by this paper
• Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.

  2009cited by this paper
• Rifampicin serum levels in childhood tuberculosis.

  2009cited by this paper
• Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

  2009cited by this paper
• Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

  2009cited by this paper
• Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

  2009cited by this paper
• Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations

  2007cited by this paper
• Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin

  2007cited by this paper
• Low Levels of Pyrazinamide and Ethambutol in Children with Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection

  2006cited by this paper
• Ethambutol dosage for the treatment of children: literature review and recommendations.

  2006cited by this paper
• Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis.

  2006cited by this paper
• Isoniazid pharmacokinetics in children treated for respiratory tuberculosis

  2005cited by this paper
• Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

  2005cited by this paper
• The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.

  2005cited by this paper
• Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

  2005cited by this paper
• Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis

  2003cited by this paper
• Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.

  1999cited by this paper
• The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.

  1997cited by this paper
• Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee.

  1995cited by this paper
• Ethambutol and rifampicin serum levels in children: Second report on the combined administration of ethambutol and rifampicin

  1973cited by this paper

• Adequacy of the 10 mg/kg Daily Dose of Antituberculosis Drug Isoniazid in Infants under 6 Months of Age

  2023cites this paper
• Adequacy of WHO weight-band dosing and fixed-dose combinations for the treatment of TB in children.

  2023cites this paper
• Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?

  2022cites this paper
• Therapeutic drug monitoring of intravenous anti-tuberculous therapy: management of an 8-month-old child with tuberculous meningitis

  2021cites this paper
• Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: a prospective population pharmacokinetic study.

  2021cites this paper
• Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations

  2021cites this paper
• Simultaneous determination of first-line anti-tuberculosis drugs and one metabolite of isoniazid by liquid chromatography/tandem mass spectrometry in patients with human immunodeficiency virus-tuberculosis coinfection

  2021cites this paper
• Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review

  2020cites this paper
• Subtherapeutic concentrations of first-line antitubercular agents in pediatric patients and its association with tuberculosis treatment outcome: protocol for a systematic review and meta-analysis

  2020cites this paper
• Antituberculosis Activity Test of N-p-Methylbenzyl-p-coumaramide (MBC) Against M. tuberculosis H37Rv

  2020cites this paper
• Treating children with tuberculosis: new weapons for an old enemy

  2019cites this paper
• Drug repurposing against arabinosyl transferase (EmbC) of Mycobacterium tuberculosis: Essential dynamics and free energy minima based binding mechanics analysis.

  2019cites this paper
• Pharmacokinetics of First-Line Anti-Tubercular Drugs

  2019cites this paper
• Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.

  2019cites this paper
• Evaluation of Dosing Guidelines for Childhood Tuberculosis: A Mathematical Modeling Study

  2019influential citation
• HIV-associated pediatric tuberculosis: prevention, diagnosis and treatment

  2018cites this paper
• Evaluation of the Adequacy of WHO Revised Dosages of the First-Line Antituberculosis Drugs in Children with Tuberculosis Using Population Pharmacokinetic Modeling and Simulations

  2018cites this paper
• Effect of TB Therapy on the Health and Nutritional Status of Infants Aged 6 Months to 5 Years Diagnosed with Latent TB

  2018cites this paper
• Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.

  2018cites this paper
• Managing latent tuberculosis infection and tuberculosis in children.

  2018cites this paper